Comprehensive medication guide to Dexmethylphenidate XR including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With insurance, generic Dexmethylphenidate XR is typically covered as a Tier 2 medication with copays ranging from $10 to $50 per month.
Estimated Cash Pricing
Generic Dexmethylphenidate XR costs $40 to $150 per month with a coupon, while brand-name Focalin XR runs $250 to $490 per month.
Medfinder Findability Score
40/100
Summarize with AI
On this page
Dexmethylphenidate XR is an extended-release CNS stimulant prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. It is the purified, pharmacologically active d-threo enantiomer of racemic methylphenidate, which means it contains only the more potent half of the methylphenidate molecule. The brand-name version is sold as Focalin XR, manufactured by Novartis Pharmaceuticals.
The extended-release formulation provides symptom control throughout the day with a single morning dose, typically lasting 8 to 12 hours. Adults typically start at 10 mg per day and may increase up to 40 mg per day, while children start at 5 mg per day with a maximum of 30 mg per day.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Dexmethylphenidate XR works as a norepinephrine-dopamine reuptake inhibitor (NDRI). It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing the availability of these neurotransmitters in the synaptic cleft. This enhanced neurotransmitter activity in the brain's prefrontal cortex helps improve attention, focus, and impulse control in people with ADHD.
The extended-release capsule uses a bi-modal release system — half the dose releases immediately and the other half releases approximately four hours later — providing consistent symptom coverage throughout the day without the need for a second dose.
5 mg extended-release capsules
10 mg extended-release capsules
15 mg extended-release capsules
20 mg extended-release capsules
25 mg extended-release capsules
30 mg extended-release capsules
35 mg extended-release capsules
40 mg extended-release capsules
Dexmethylphenidate XR has a findability score of 40 out of 100, meaning it is frequently difficult to find in stock. As of early 2026, Dexmethylphenidate XR remains on the FDA's active drug shortage list. Multiple manufacturers have various strengths on back order with no estimated release dates. The broader ADHD stimulant shortage that began in October 2022 continues to affect supply. DEA production quota limitations, increased demand, and manufacturing delays have all contributed to ongoing supply disruptions.
If your local pharmacy is out of stock, try using Medfinder to search nearby pharmacies that may have your dose available. Calling independent pharmacies rather than large chains can also improve your chances of finding it.
Because Dexmethylphenidate XR is a Schedule II controlled substance, it requires a prescription from a licensed prescriber with DEA authorization. The following types of doctors and providers commonly prescribe it:
Telehealth providers can also prescribe Dexmethylphenidate XR in many states, though regulations for controlled substance prescribing via telemedicine vary by state.
Yes, Dexmethylphenidate XR is classified as a Schedule II controlled substance by the DEA. This is the most restrictive category for drugs with accepted medical use, indicating a high potential for abuse and dependence.
As a Schedule II substance, prescriptions for Dexmethylphenidate XR cannot be called in to pharmacies — they must be written or sent electronically. Refills are not permitted; a new prescription is required each time. Most states limit prescriptions to a 30-day supply, though some allow up to 90 days. These restrictions can make it more challenging to obtain, especially during shortages.
Serious side effects can include cardiovascular events (increased blood pressure and heart rate), psychiatric symptoms such as psychosis or mania, peripheral vasculopathy (Raynaud's phenomenon), and growth suppression in children with long-term use. Contact your doctor immediately if you experience chest pain, shortness of breath, or unusual behavioral changes.
Know what you need? Skip the search.
Methylphenidate ER (Concerta, Ritalin LA)
Racemic methylphenidate extended-release with a similar mechanism, containing both d- and l-isomers. Widely available in generic form.
Adderall XR (Mixed Amphetamine Salts)
An extended-release amphetamine-based stimulant that targets dopamine and norepinephrine release rather than reuptake. Note: also affected by the ADHD stimulant shortage.
Vyvanse (Lisdexamfetamine)
A prodrug of dextroamphetamine with a smoother onset and lower abuse potential. Now available in generic form as of 2023.
Strattera (Atomoxetine)
A non-stimulant ADHD medication and selective norepinephrine reuptake inhibitor. Not a controlled substance, so it is easier to prescribe and fill.
Prefer Dexmethylphenidate XR? We can find it.
MAO Inhibitors
moderateContraindicated. Concurrent use or use within 14 days of an MAOI can cause hypertensive crisis.
Antihypertensive medications
moderateDexmethylphenidate may reduce the efficacy of blood pressure medications.
Coumarin anticoagulants (Warfarin)
moderateDexmethylphenidate may increase anticoagulant blood levels, requiring dose adjustments.
Anticonvulsants (Phenobarbital, Phenytoin)
moderateMay increase levels of these medications.
Tricyclic antidepressants
moderateMay increase TCA blood levels and risk of side effects.
Serotonergic drugs (SSRIs, SNRIs, Triptans)
moderateRisk of serotonin syndrome when combined.
Clonidine
majorSerious adverse events have been reported with concurrent use.
Dexmethylphenidate XR remains an effective and widely prescribed treatment for ADHD, but the ongoing stimulant shortage continues to make it challenging to find in stock in 2026. With a findability score of just 40 out of 100, patients should plan ahead and explore multiple pharmacy options when filling prescriptions.
Generic versions offer significant savings at $40 to $150 per month compared to $250 to $490 for brand-name Focalin XR. Novartis also offers a savings card and patient assistance program for eligible patients. If you're struggling to locate Dexmethylphenidate XR, use Medfinder to search pharmacies near you that currently have it in stock, and consider asking your doctor about alternative ADHD medications as a backup plan.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini